glp 1 stocks 2025 GLP-1 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Financial Express | A ₹1,000

Read highlights from the released 2025 Standards of Care, including recommendations for CGM use in type 2 diabetes for the first time, the use of GLP-1 drugs for kidney and heart benefits and a warning of DKA risk in recreational marijuana use.

Eli Lillys triple agonist demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes.

Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

C., Shin, H

(1)These statements have not been evaluated by the Food and Drug Administration

In addition to their glycemic effects, DPP-4 inhibitors have the potential to decrease bone resorption, increase bone formation, and reduce the incidence of osteoporosis and fractures